Clinical Trial Update: A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight [Phase 1]

View source ↗

Summary

Phase 1 study of Eloralintide (LY3841136) in Chinese participants with obesity or overweight completed; the trial aimed to assess safety, tolerability, and phar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Eloralintide (LY3841136)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obesity, Overweight | Phase 1 | Status: COMPLETED